European journal of nuclear medicine and molecular imaging · 2026
Radiolabelled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with metastatic pheochromocytoma or paraganglioma: a retrospective pilot study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schmidt Felix, Lider Sofia-Maria, McDougall Lisa, Eigler Christopher, Bernhardt Peter, Mushaweh Abdulrafee, Bauman Andreas, Fani Melpomeni, Christ Emanuel, Wild Damian
Аннотация
PURPOSE: Metastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumours with limited therapeutic options. Peptide receptor radionuclide therapy (PRRT) using somatostatin receptor (SSTR) antagonists (e.g. [177Lu]Lu-DOTA-JR11) may achieve higher tumour and organ absorbed doses compared with standard SSTR agonist therapy (e.g. [177Lu]Lu-DOTA-TOC). This study aimed to perform an intra-patient comparison of tumour and organ dosimetry between [177Lu]Lu-DOTA-TOC and [177Lu]Lu-DOTA-JR11 in patients with mPPGLs refractory to conventional therapies. Secondary endpoints included safety and exploratory clinical efficacy of [177Lu]Lu-DOTA-JR11.
METHODS: In this retrospective pilot study, 6 patients with mPPGLs received 1-2 cycles of [177Lu]Lu-DOTA-TOC (~ 7.4 GBq/cycle), followed by 1-2 cycles of [177Lu]Lu-DOTA-JR11 (2 GBq/m2 × body surface area) at an interval of 10-12 weeks. Endpoints included estimation of tumour and organ absorbed doses, assessment of safety according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and symptoms, and evaluation of progression-free survival (PFS) before and after [177Lu]Lu-DOTA-JR11 therapy.
RESULTS: Intra-patient comparison showed that the median tumour absorbed dose per cycle was 1.3-fold higher (range 0.9-3.5) with [177Lu]Lu-DOTA-JR11 than with [177Lu]Lu-DOTA-TOC. This was associated with longer PFS after [177Lu]Lu-DOTA-JR11 (12.5 months; range 6 - >20) versus PFS before inclusion (3.5 months; range 1-9). The most severe adverse event was grade 3 lymphopenia in one patient. No thrombocytopenia, neutropenia, creatinine elevation or alanine aminotransferase elevation was observed.
CONCLUSION: [177Lu]Lu-DOTA-JR11 resulted in higher tumour absorbed doses than [177Lu]Lu-DOTA-TOC and was associated with longer post-treatment PFS than PFS before inclusion in this small cohort. Treatment was well tolerated, supporting further prospective evaluation in patients with mPPGLs.
METHODS: In this retrospective pilot study, 6 patients with mPPGLs received 1-2 cycles of [177Lu]Lu-DOTA-TOC (~ 7.4 GBq/cycle), followed by 1-2 cycles of [177Lu]Lu-DOTA-JR11 (2 GBq/m2 × body surface area) at an interval of 10-12 weeks. Endpoints included estimation of tumour and organ absorbed doses, assessment of safety according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and symptoms, and evaluation of progression-free survival (PFS) before and after [177Lu]Lu-DOTA-JR11 therapy.
RESULTS: Intra-patient comparison showed that the median tumour absorbed dose per cycle was 1.3-fold higher (range 0.9-3.5) with [177Lu]Lu-DOTA-JR11 than with [177Lu]Lu-DOTA-TOC. This was associated with longer PFS after [177Lu]Lu-DOTA-JR11 (12.5 months; range 6 - >20) versus PFS before inclusion (3.5 months; range 1-9). The most severe adverse event was grade 3 lymphopenia in one patient. No thrombocytopenia, neutropenia, creatinine elevation or alanine aminotransferase elevation was observed.
CONCLUSION: [177Lu]Lu-DOTA-JR11 resulted in higher tumour absorbed doses than [177Lu]Lu-DOTA-TOC and was associated with longer post-treatment PFS than PFS before inclusion in this small cohort. Treatment was well tolerated, supporting further prospective evaluation in patients with mPPGLs.